<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Global X Aging Population Etf — News on 6ix</title>
<link>https://6ix.com/company/global-x-aging-population-etf</link>
<description>Latest news and press releases for Global X Aging Population Etf on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/global-x-aging-population-etf" rel="self" type="application/rss+xml" />
<item>
<title>IFF Launches PureStrong™, a Probiotic Made Specifically for Dogs</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/iff-launches-purestrongtm-a-probiotic-made-specifically-for-dogs-34</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/iff-launches-purestrongtm-a-probiotic-made-specifically-for-dogs-34</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—is introducing PureStrong™, a</description>
</item>
<item>
<title>Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/dermata-receives-notice-of-acceptance-of-australian-patent-application-for-topical-application-of-dermal-fillers-with-its-bioneedle-delivery-system-24</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/dermata-receives-notice-of-acceptance-of-australian-patent-application-for-topical-application-of-dermal-fillers-with-its-bioneedle-delivery-system-24</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has</description>
</item>
<item>
<title>InterDigital signs license agreement with Buffalo Americas; adds new DTV agreements</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/interdigital-signs-license-agreement-with-buffalo-americas-adds-new-dtv-agreements-2</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/interdigital-signs-license-agreement-with-buffalo-americas-adds-new-dtv-agreements-2</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>WILMINGTON, Del., April 02, 2026 (GLOBE NEWSWIRE) -- InterDigital, Inc. (Nasdaq: IDCC), a wireless, video, and AI technology research and development company,</description>
</item>
<item>
<title>PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine-40</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/puretech-announces-publication-of-phase-2b-elevate-ipf-trial-results-in-the-american-journal-of-respiratory-and-critical-care-medicine-40</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Deupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis</description>
</item>
<item>
<title>Pineapple Financial Deepens Strategic Relationship with Canary Capital</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/pineapple-financial-deepens-strategic-relationship-with-canary-capital-22</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/pineapple-financial-deepens-strategic-relationship-with-canary-capital-22</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Appoints Digital Asset Treasury Advisor, Bringing Institutional Portfolio Construction and Capital Strategy Expertise Toronto, Ontario--(Newsfile Corp. -</description>
</item>
<item>
<title>Dalrada Technology Group, Inc. Announces Agreement Supporting Ultra-High Temperature Industrial Heat Pump Development</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/dalrada-technology-group-inc-announces-agreement-supporting-ultra-high-temperature-industrial-heat-pump-development-13</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/dalrada-technology-group-inc-announces-agreement-supporting-ultra-high-temperature-industrial-heat-pump-development-13</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>ESCONDIDO, CA / ACCESS Newswire / April 2, 2026 / Dalrada Technology Group, Inc. (the "Company" or "Dalrada") (OTCID:DHTI), a leader in advanced climate</description>
</item>
<item>
<title>Nanox Signs Distribution Agreement with Integrity Medical Service, Inc. to Deploy Nanox.ARC Systems</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/nanox-signs-distribution-agreement-with-integrity-medical-service-inc-to-deploy-nanoxarc-systems-50</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/nanox-signs-distribution-agreement-with-integrity-medical-service-inc-to-deploy-nanoxarc-systems-50</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>New regional partnership strengthens Nanox’s presence and service support across outpatient imaging settings in Colorado, Wyoming and the western parts of</description>
</item>
<item>
<title>Cycurion Goes on Offense: Initiates Legal Action and Seeks Millions in Damages Against ACCESS Newswire and Those Responsible for Disseminating the Unauthorized and Fraudulent Release</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/cycurion-goes-on-offense-initiates-legal-action-and-seeks-millions-in-damages-against-access-newswire-and-those-responsible-for-disseminating-the-unauthorized-and-fraudulent-release-1</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/cycurion-goes-on-offense-initiates-legal-action-and-seeks-millions-in-damages-against-access-newswire-and-those-responsible-for-disseminating-the-unauthorized-and-fraudulent-release-1</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MCLEAN, Va., April 02, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity and</description>
</item>
<item>
<title>Olenox Announces Results of Annual Stockholder Meeting</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/olenox-announces-results-of-annual-stockholder-meeting-23</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/olenox-announces-results-of-annual-stockholder-meeting-23</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CONROE, TX / ACCESS Newswire / April 2, 2026 / Olenox Industries, Inc. (NASDAQ:OLOX) ("Olenox" or the "Company") is pleased to announce the results of its</description>
</item>
<item>
<title>Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/ultragenyx-announces-us-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia-6</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/ultragenyx-announces-us-fda-acceptance-of-bla-resubmission-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to</description>
</item>
<item>
<title>Orion to Exhibit at LEDucation 2026</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/orion-to-exhibit-at-leducation-2026-24</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/orion-to-exhibit-at-leducation-2026-24</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MANITOWOC, Wis., April 02, 2026 (GLOBE NEWSWIRE) -- Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting,</description>
</item>
<item>
<title>BrightSpire Capital, Inc. Announces First Quarter 2026 Earnings Release and Conference Call Dates</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/brightspire-capital-inc-announces-first-quarter-2026-earnings-release-and-conference-call-dates-33</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/brightspire-capital-inc-announces-first-quarter-2026-earnings-release-and-conference-call-dates-33</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK--(BUSINESS WIRE)-- BrightSpire Capital, Inc. (NYSE: BRSP) (“BrightSpire Capital” or the “Company”) today announced it will release first quarter</description>
</item>
<item>
<title>Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies-6</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/biodexa-announces-partnership-with-syngene-to-manufacture-mtx240-gmp-clinical-trial-supplies-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX)</description>
</item>
<item>
<title>Braiin and Home Announce Exclusive Strategic Partnership to Pioneer "LiveTech" and Build AI-Native Living Infrastructure Platform</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/braiin-and-home-announce-exclusive-strategic-partnership-to-pioneer-livetech-and-build-ai-native-living-infrastructure-platform-14</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/braiin-and-home-announce-exclusive-strategic-partnership-to-pioneer-livetech-and-build-ai-native-living-infrastructure-platform-14</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>A category-defining partnership combining AI, payments and embedded distribution NEW YORK, NY AND LONDON, UK / ACCESS Newswire / April 2, 2026 / Braiin</description>
</item>
<item>
<title>ZenaTech Initiates New Operations in Ukraine to Accelerate Production of Counter-UAS Interceptor Systems</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/zenatech-initiates-new-operations-in-ukraine-to-accelerate-production-of-counter-uas-interceptor-systems-5</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/zenatech-initiates-new-operations-in-ukraine-to-accelerate-production-of-counter-uas-interceptor-systems-5</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Ukraine operations will be structured for full regulatory compliance to support U.S. defense and Gulf nation adoption VANCOUVER, British Columbia, April 02,</description>
</item>
<item>
<title>Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/worksport-announces-cortm-portable-energy-system-is-now-fully-certified-including-key-ul-and-csa-approvals-for-north-american-retail-and-commercial-distribution-19</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/worksport-announces-cortm-portable-energy-system-is-now-fully-certified-including-key-ul-and-csa-approvals-for-north-american-retail-and-commercial-distribution-19</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Final safety and compliance approvals complete; certification package supports broader sales across retail, fleet, distributor, and commercial channels WEST</description>
</item>
<item>
<title>Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york-2</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/abeona-therapeuticsr-announces-new-qualified-treatment-center-for-zevaskynr-in-new-york-2</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of NewYork-Presbyterian/Columbia University</description>
</item>
<item>
<title>Intelligent Bio Solutions Completes Clinical Cut-off Study, Advances FDA 510(k) Clinical Program Targeting Multi-Billion-Dollar U.S. Drug Screening Market</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510k-clinical-program-targeting-multi-billion-dollar-us-drug-screening-market-2</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/intelligent-bio-solutions-completes-clinical-cut-off-study-advances-fda-510k-clinical-program-targeting-multi-billion-dollar-us-drug-screening-market-2</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Study results finalized on schedule support FDA clearance and planned U.S. commercial launch Company advances second phase of clinical program for 510(k)</description>
</item>
<item>
<title>CSW Industrials Increases Quarterly Dividend by 11% to $0.30 Per Share and Repurchases $35M in Shares During the Fiscal Fourth Quarter of 2026</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/csw-industrials-increases-quarterly-dividend-by-11percent-to-dollar030-per-share-and-repurchases-dollar35m-in-shares-during-the-fiscal-fourth-quarter-of-2026-7</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/csw-industrials-increases-quarterly-dividend-by-11percent-to-dollar030-per-share-and-repurchases-dollar35m-in-shares-during-the-fiscal-fourth-quarter-of-2026-7</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>DALLAS, April 02, 2026 (GLOBE NEWSWIRE) -- CSW Industrials, Inc. (NYSE: CSW) announced today that its Board of Directors has declared a regular quarterly cash</description>
</item>
<item>
<title>RXO Schedules First-Quarter 2026 Earnings and Investor Conference Call for May 7, 2026</title>
<link>https://6ix.com/company/global-x-aging-population-etf/news/rxo-schedules-first-quarter-2026-earnings-and-investor-conference-call-for-may-7-2026-32</link>
<guid isPermaLink="true">https://6ix.com/company/global-x-aging-population-etf/news/rxo-schedules-first-quarter-2026-earnings-and-investor-conference-call-for-may-7-2026-32</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CHARLOTTE, N.C.--(BUSINESS WIRE)-- RXO (NYSE: RXO) will issue its first-quarter financial results before the opening of the New York Stock Exchange on</description>
</item>
</channel>
</rss>